In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

Explore the latest insights on clinical trial data and real-world evidence for innovative cancer therapies, highlighting ...

Tecvayli and Darzalex combination shows unprecedented progression-free survival in relapsed/refractory multiple myeloma, ...

The FDA issued draft guidance Jan. 21 proposing the use of minimal residual disease and complete response as primary endpoints to support accelerated approval of drugs for multiple myeloma. The draft ...

A Prescription Drug User Fee Act target date of July 10, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application ...

“Tecvayli Treatment Combo Improves Outcomes in Relapsed/Refractory Myeloma,” CURE; ...

Bispecific antibodies talquetamab and teclistamab show promise for advanced multiple myeloma, including extramedullary disease, with safe administration in community settings emphasized. CEPHEUS study ...

The Multiple Myeloma Research Foundation announced this week the launch of a centralized data hub to help identify new treatment targets and thus accelerate the delivery of precision medicine. The ...

The National Comprehensive Cancer Network provides a list of preferred primary therapy regimens for transplant-eligible and nontransplant candidates and lists drugs recommended for maintenance therapy ...

Are an adult with relapsed or refractory multiple myeloma Have tried at least four previous lines of treatments for multiple myeloma, including: Immune system modulators (help boost the immune system ...

One of the major stories in multiple myeloma in 2024 was the comeback of belantamab mafodotin (Blenrep) after it had been pulled from the market in 2022. In 2020, belantamab mafodotin, an anti-B-cell ...